An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies

Trial Profile

An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs ABBV 621 (Primary)
  • Indications Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 30 Nov 2017 Planned End Date changed from 16 Nov 2019 to 29 Apr 2020.
    • 31 Oct 2017 Planned End Date changed from 27 Feb 2020 to 16 Nov 2019.
    • 30 Mar 2017 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top